Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Robin Vos and Iwein Gyselinck.
Robin Vos
Connection Strength
1.505
Iwein Gyselinck
  1. Rationale for azithromycin in COVID-19: an overview of existing evidence. BMJ Open Respir Res. 2021 01; 8(1).
    View in: PubMed
    Score: 0.922
  2. Correction to: Direct antivirals working against the novel coronavirus: azithromycin (DAWn-AZITHRO), a randomized, multicenter, open-label, adaptive, proof-of-concept clinical trial of new antivirals working against SARS-CoV-2-azithromycin trial. Trials. 2021 Mar 05; 22(1):187.
    View in: PubMed
    Score: 0.233
  3. Direct antivirals working against the novel coronavirus: azithromycin (DAWn-AZITHRO), a randomized, multicenter, open-label, adaptive, proof-of-concept clinical trial of new antivirals working against SARS-CoV-2-azithromycin trial. Trials. 2021 Feb 09; 22(1):126.
    View in: PubMed
    Score: 0.232
  4. Corrigendum to "itraconazole for COVID-19: Preclinical studies and a proof-of-concept randomized clinical trial Laurens". EBioMedicine. 2021 Jul; 69:103454.
    View in: PubMed
    Score: 0.060
  5. Itraconazole for COVID-19: preclinical studies and a proof-of-concept randomized clinical trial. EBioMedicine. 2021 Apr; 66:103288.
    View in: PubMed
    Score: 0.058
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.